pcDNA3.1-GSDMD_29-270
(Plasmid
#218232)
-
PurposeGasdermin-D_29-270 is a non-functional GSDMD formed by two SARS-CoV-2 3CLpro cleavages. Transfection in HEK293 cells showed no pore-forming activity or induction of pyroptosis
-
Depositing Lab
-
Depositing OrganizationUniversity of British Columbia
Located in Canada -
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 218232 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 * | |
| DNA | 218232-D50 | 50 μg of DNA in Tris buffer | $495 * | ||
| DNA | 218232-D100 | 100 μg of DNA in Tris buffer | $585 * | ||
* Log in to view industry pricing.
Backbone
-
Vector backbonepcDNA3.1
- Backbone size w/o insert (bp) 5446
- Total vector size (bp) 6119
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Growth instructionsE. coli Top10 can also be used
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameGSDMD
-
SpeciesH. sapiens (human)
-
Insert Size (bp)723
-
Mutationconstruct only codes for amino acids 29-270
-
GenBank IDNM_024736.7
-
Entrez GeneGSDMD (a.k.a. DF5L, DFNA5L, FKSG10, GSDMDC1)
-
Tag
/ Fusion Protein
- flag (C terminal on insert)
Cloning Information
- Cloning method Other
- 5′ sequencing primer N/A
- 3′ sequencing primer N/A
- (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byGenscript
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Genscript's used their original construct OHu03821D (NM_024736.7) to clone our customized construct. Cloning method: CloneEZ;Vector: pcDNA3.1+/C-(K)DYK. The insert is a truncated construct coding for aa 29-270 of Gasdermin-D (GSDMD).
DNA (Catalog # 218232-D50)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 50 μg
- Concentration 1 μg/μL
- Pricing $495 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
DNA (Catalog # 218232-D100)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 100 μg
- Concentration 1 μg/μL
- Pricing $585 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA3.1-GSDMD_29-270 was a gift from Christopher Overall (Addgene plasmid # 218232 ; http://n2t.net/addgene:218232 ; RRID:Addgene_218232) -
For your References section:
SARS-CoV-2 3CL(pro) (main protease) regulates caspase activation of gasdermin-D/E pores leading to secretion and extracellular activity of 3CL(pro). Grin PM, Baid K, de Jesus HCR, Kozarac N, Bell PA, Jiang SZ, Kappelhoff R, Butler GS, Leborgne NGF, Pan C, Pablos I, Machado Y, Vederas JC, Kim H, Benarafa C, Banerjee A, Overall CM. Cell Rep. 2024 Dec 24;43(12):115080. doi: 10.1016/j.celrep.2024.115080. Epub 2024 Dec 12. 10.1016/j.celrep.2024.115080 PubMed 39673710